{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:34:01Z","timestamp":1786988041353,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009109","name":"Pharmaceuticals Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007659","name":"Bayer Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejca.2025.115513","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T11:51:55Z","timestamp":1747396315000},"page":"115513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Radiological progression-free survival as a surrogate for overall survival in patients with metastatic hormone-sensitive prostate cancer: A bivariate meta-analysis"],"prefix":"10.1016","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-0548","authenticated-orcid":false,"given":"Neal","family":"Shore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia K.","family":"Morgans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Boegemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6013-3276","authenticated-orcid":false,"given":"Elaine","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3438-4853","authenticated-orcid":false,"given":"Noman","family":"Paracha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Serafini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6680-4074","authenticated-orcid":false,"given":"Divya","family":"Pushkarna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7975-8823","authenticated-orcid":false,"given":"Mir-Masoud","family":"Pourrahmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Kurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith R.","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115513_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"10.1016\/j.ejca.2025.115513_bib2","article-title":"SMARTphone-based, early cardiac REHABilitation in patients with acute coronary syndromes: a randomized controlled trial","volume":"27","author":"Yudi","year":"2020","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.ejca.2025.115513_bib3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115513_bib4","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115513_bib5","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115513_bib6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.eururo.2020.03.019","article-title":"Effect of enzalutamide plus androgen deprivation therapy on health-related quality of life in patients with metastatic hormone-sensitive prostate cancer: an analysis of the ARCHES randomised, placebo-controlled, phase 3 study","volume":"78","author":"Stenzl","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2025.115513_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115513_bib8","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u00d72 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.115513_bib9","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115513_bib10","unstructured":"Lowrance W., Dreicer R., Jarrard D. Advanced Prostate Cancer: AUA\/SUO Guideline Using AUA Guidelines."},{"key":"10.1016\/j.ejca.2025.115513_bib11","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/14737140.2017.1316196","article-title":"Surrogate endpoints for overall survival in lung cancer trials: a review","volume":"17","author":"Fiteni","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ejca.2025.115513_bib12","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41416-020-01050-w","article-title":"A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer","volume":"123","author":"Cooper","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2025.115513_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1183\/09031936.00190310","article-title":"Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations","volume":"39","author":"Berghmans","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejca.2025.115513_bib14","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1158\/1078-0432.CCR-16-1293","article-title":"FDA approval: alectinib for the treatment of metastatic, ALK-positive non-small cell lung cancer following crizotinib","volume":"22","author":"Larkins","year":"2016","journal-title":"Clin Cancer Res: J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2025.115513_bib15","doi-asserted-by":"crossref","first-page":"e533","DOI":"10.1016\/j.cllc.2018.04.004","article-title":"ADAURA: phase III, double-blind, randomized study of osimertinib versus placebo in EGFR mutation-positive early-stage NSCLC after complete surgical resection","volume":"19","author":"Wu","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ejca.2025.115513_bib16","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1200\/JCO.2013.50.3201","article-title":"Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy","volume":"31","author":"Halabi","year":"2013","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115513_bib17","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e13658","article-title":"EY-s. Recent analysis of frequency of surrogate end points used in oncology clinical trials 2006-2022","volume":"41","author":"Chitkara","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115513_bib18","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.jval.2019.03.007","article-title":"Selection of endpoints in clinical trials: trends in european marketing authorization practice in oncological indications","volume":"22","author":"Kordecka","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.ejca.2025.115513_bib19","doi-asserted-by":"crossref","DOI":"10.1017\/S0266462325000017","article-title":"Use of surrogate endpoints in health technology assessment: a review of selected NICE technology appraisals in oncology","volume":"41","author":"Wheaton","year":"2025","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.ejca.2025.115513_bib20","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials: definition and operational criteria","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2025.115513_bib21","unstructured":"Cda-Am, Icer, Nice, Adhac, Zin, Iets, et al. Surrogate endpoints in cost-effectiveness analysis for use in health technology assessment. 2025."},{"key":"10.1016\/j.ejca.2025.115513_bib22","first-page":"20","article-title":"Multivariate meta-analysis of summary data for combining treatment effects on correlated outcomes and evaluating surrogate endpoints","author":"Bujkiewicz","year":"2019","journal-title":"NICE DSU Tech Support Doc"},{"key":"10.1016\/j.ejca.2025.115513_bib23","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.23.01535","article-title":"Radiographic progression-free survival and clinical progression-free survival as potential surrogates for overall survival in men with metastatic hormone-sensitive prostate cancer","volume":"42","author":"Halabi","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115513_bib24","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1200\/JCO.24.00210","article-title":"Is it premature to accept radiographic progression-free survival as a surrogate end point in metastatic hormone-sensitive prostate cancer?","volume":"42","author":"Garcia","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115513_bib25","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200195","article-title":"Meta-analysis of candidate surrogate end points in advanced prostate cancer","volume":"2","author":"Gharzai","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ejca.2025.115513_bib26","unstructured":"Higgins J.P.T., Thomas J., Chandler J., Cumpston M., Li T., Page M.J., et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated 2023): Cochrane; 2023."},{"key":"10.1016\/j.ejca.2025.115513_bib27","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2025.115513_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ejca.2025.115513_bib29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1471-2288-12-27","volume":"12","author":"Lassere","year":"2012","journal-title":"BMC Med Res Method"},{"key":"10.1016\/j.ejca.2025.115513_bib30","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00345-013-1206-0","article-title":"Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial","volume":"32","author":"Verhagen","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.ejca.2025.115513_bib31","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.e15000","article-title":"A randomized placebo-controlled trial of daily high-dose oral risedronate in men with metastatic prostate cancer commencing androgen deprivation therapy (ADT)","volume":"28","author":"Sweeney","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925002953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925002953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:35:21Z","timestamp":1762342521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925002953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":31,"alternative-id":["S0959804925002953"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115513","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiological progression-free survival as a surrogate for overall survival in patients with metastatic hormone-sensitive prostate cancer: A bivariate meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115513","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115513"}}